Phase 3 trial for localized prostate cancer should be completed in December 2024

[Maxone73]

CAN-2409 is an immunotherapy drug currently in a Phase 3 clinical trial (PrTK03, NCT01436968) for individuals with intermediate-high risk localized prostate cancer.

The trial, which is expected to conclude in December 2024, is evaluating the effectiveness of CAN-2409 in combination with radiation therapy. This placebo-controlled study involves 711 participants from the US and Puerto Rico who undergo monitoring every six months for a duration of five years.

The primary objective of the trial is to determine disease-free survival rates. CAN-2409 functions by utilizing an inactivated herpes virus as a vehicle to transport a specific gene directly into cancer cells. Subsequent administration of Valtrex (valacyclovir), an anti-herpetic medication, aims to eliminate the cells containing the introduced gene.

ONCOLYTIC VIRUSES ARE ON THE MOVE!

prostatewarriors.com/2024/1...

[Mikeski]

Interesting approach! At least to me, a software engineer that didn’t fair well in Bio

[Rolphs]

Fascinating! I remember growing up reading that they thought cancer was a form of virus. Now they may use inactivated virus cells to fight the damn things.

[NanoMRI]

I do wonder how it is know for certain the cancer is "localized"; and how is this defined? Is the radiation alone considered inadequate?

For my recently initiated doublet immunotherapy for metastatic liver melanoma, 2 of 4 treatments completed, surgery and RT were discussed however the well-thought decision is to first evaluate treatment effectiveness. Currently awaiting MRI reaults.

[Maxone73 in reply to NanoMRI]

I hope everything will work well. Usually melanoma responds greatly to immunotherapy! Fight on!

[NanoMRI in reply to Maxone73]

Thank you! Just got my evaluation MRI results. I am at midpoint of four doublet immunotherapy treatments - MRI report reads "Decreased size of metastatic lesion" - about 50% reduction in singular 2cm liver met. Hopefully PC immunotherapy will advance.